AstraZeneca and Merck's Lynparza gets FDA nod for early breast cancer
Povozniuk/iStock via Getty Images         

The U.S. FDA has granted an additional indication for AstraZeneca (NASDAQ:AZN) and Merck's (NYSE:MRK)
Lynparza (olaparib) as anÂ adjuvant treatment for a type of early-stage breast cancer.
The new indication is for germline BRCA-mutated HER2-negative high-risk early breast cancer in those already treated with chemotherapy either before or after surgery.
Phase 3 data showed that Lynparza led toÂ a statistically significant improvement in invasive disease-free survival , reducing the risk of invasive breast cancer recurrences, second cancers or death by 42% compared to placebo.
Read why Seeking Alpha contributor Nathan Aisenstadt considers AstraZeneca (AZN) a buy.